A monoclonal antibody against human UL16-binding protein 3

Hybridoma

Volumn 31, Issue 3, 2012, Pages 203-208

  Mao, Chaoming ^a   Qin, Wei ^a,b   Chen, Deyu ^a   Yuan, Guoyue ^a   Mou, Xiao ^a   Bao, Danxia ^b   Wu, Wei ^a   Xu, Huaxi ^b   Wang, Shengjun ^b  

^a AFFILIATED HOSPITAL OF JIANGSU UNIVERSITY   (China)

^b JIANGSU UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CELL SURFACE PROTEIN; COMPLEMENTARY DNA; LIGAND; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MESSENGER RNA; MONOCLONAL ANTIBODY; NATURAL KILLER CELL RECEPTOR NKG2D; RECOMBINANT PROTEIN; UL16 BINDING PROTEIN 3; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; CELL FUSION; COLORECTAL CANCER; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; EXPRESSION VECTOR; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYBRIDOMA; IMMUNIZATION; IMMUNOHISTOCHEMISTRY; MAJOR HISTOCOMPATIBILITY COMPLEX; MOLECULAR CLONING; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PURIFICATION; RECOMBINANT PLASMID; SPLEEN; T LYMPHOCYTE; TUMOR CELL; WESTERN BLOTTING;

ANIMALS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIBODY AFFINITY; CELL LINE; COLORECTAL NEOPLASMS; ESCHERICHIA COLI; FEMALE; GPI-LINKED PROTEINS; HUMANS; HYBRIDOMAS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MICE, INBRED BALB C; RECOMBINANT FUSION PROTEINS;

ESCHERICHIA COLI; MUS; PROKARYOTA;

EID: 84864686241     PISSN: 15540014     EISSN: 15578348     Source Type: Journal    
DOI: 10.1089/hyb.2011.0113     Document Type: Article

References (27)

1. Cao W, and He W: UL16 binding proteins. Immunobiology 2004;209:283-290. (Pubitemid 39377864)
2. Sutherland CL, Chalupny NJ, Schooley K, VandenBos T, Kubin M, and Cosman D: UL16-binding proteins, novel MHC class I-related proteins, bind to NKG2D and activate multiple signaling pathways in primary NK cells. J Immunol 2002;168:671-679. (Pubitemid 34049567)
3. Groh V, Rhinehart R, Randolph-Habecker J, Topp MS, Riddell SR, and Spies T: Costimulation of CD8alphabeta T cells by NKG2D via engagement by MIC induced on virusinfected cells. Nat Immunol 2001;2:255-260. (Pubitemid 33706003)
4. Das H, Groh V, Kuijl C, Sugita M, Morita CT, Spies T, and Bukowski JF: MICA engagement by human Vgamma2Vdelta2 T cells enhances their antigen-dependent effector function. Immunity 2001;15:83-93. (Pubitemid 32728322)
5. Diefenbach A, Tomasello E, Lucas M, Jamieson AM, Hsia JK, Vivier E, and Raulet DH: Selective associations with signaling proteins determine stimulatory versus costimulatory activity of NKG2D. Nat Immunol 2002;3:1142-1149. (Pubitemid 35469698)
6. Gilfillan S, Ho EL, Cella M, Yokoyama WM, and Colonna M: NKG2D recruits two distinct adapters to trigger NK cell activation and costimulation. Nat Immunol 2002;3:1150-1155. (Pubitemid 35469699)
7. Maasho K, Opoku-Anane J, Marusina AI, Coligan JE, and Borrego F: NKG2D is a costimulatory receptor for human naive CD8+ T cells. J Immunol 2005;174:4480-4484.
8. Markiewicz MA, Carayannopoulos LN, Naidenko OV, Matsui K, Burack WR, Wise EL, Fremont DH, Allen PM, Yokoyama WM, Colonna M, and Shaw AS: Costimulation through NKG2D enhances murine CD8 + CTL function: similarities and differences between NKG2D and CD28 costimulation. J Immunol 2005;175:2825-2833. (Pubitemid 41170499)
9. Rincon-Orozco B, Kunzmann V, Wrobel P, Kabelitz D, Steinle A, and Herrmann T: Activation of V gamma 9V delta 2 T cells by NKG2D. J Immunol 2005;175:2144-2151. (Pubitemid 41113819)
10. Meresse B, Chen Z, Ciszewski C, Tretiakova M, Bhagat G, Krausz TN, Raulet DH, Lanier LL, Groh V, Spies T, Ebert EC, Green PH, and Jabri B: Coordinated induction by IL15 of a TCR-independent NKG2D signaling pathway converts CTL into lymphokine-activated killer cells in celiac disease. Immunity 2004;21:357-366. (Pubitemid 39208337)
11. Dhanji S, Teh SJ, Oble D, Priatel JJ, and Teh HS: Self-reactive memory-phenotype CD8 T cells exhibit both MHC-restricted and non-MHC-restricted cytotoxicity: a role for the T-cell receptor and natural killer cell receptors. Blood 2004;104: 2116-2123. (Pubitemid 39297866)
12. Verneris MR, Karami M, Baker J, Jayaswal A, and Negrin RS: Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8 + T cells. Blood 2004;103:3065-3072. (Pubitemid 38451682)
13. Maccalli C, Pende D, Castelli C, Mingari MC, Robbins PF, and Parmiani G: NKG2D engagement of colorectal cancerspecific T cells strengthens TCR-mediated antigen stimulation and elicits TCR independent anti-tumor activity. Eur J Immunol 2003;33:2033-2043. (Pubitemid 37120876)
14. Nitahara A, Shimura H, Ito A, Tomiyama K, Ito M, and Kawai K: NKG2D ligation without T cell receptor engagement triggers both cytotoxicity and cytokine production in dendritic epidermal T cells. J Invest Dermatol 2006;126:1052-1058.
15. Poggi A, Venturino C, Catellani S, Clavio M, Miglino M, Gobbi M, Steinle A, Ghia P, Stella S, Caligaris-Cappio F, and Zocchi MR: Vdelta1 T lymphocytes from B-CLL patients recognize ULBP3 expressed on leukemic B cells and upregulated by trans-retinoic acid. Cancer Res 2004;64:9172-9179. (Pubitemid 39665533)
16. Groh V, Wu J, Yee C, and Spies T: Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 2002;419:734-738. (Pubitemid 35177960)
17. Salih HR, Rammensee HG, and Steinle A: Cutting edge: down-regulation of MICA on human tumors by proteolytic shedding. J Immunol 2002;169:4098-4102. (Pubitemid 35178177)
18. Salih HR, Antropius H, Gieseke F, Lutz SZ, Kanz L, Rammensee HG, and Steinle A: Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. Blood 2003;102:1389-1396. (Pubitemid 36988048)
19. Waldhauer I, and Steinle A: Proteolytic release of soluble UL16-binding protein 2 from tumor cells. Cancer Res 2006; 66:2520-2526.
20. Song H, Kim J, Cosman D, Choi I: Soluble ULBP suppresses natural killer cell activity via down-regulating NKG2D expression. Cell Immunol 2006;239:22-30. (Pubitemid 43927656)
21. Holdenrieder S, Stieber P, Peterfi A, Nagel D, Steinle A, and Salih HR: Soluble MICB in malignant diseases: analysis of diagnostic significance and correlation with soluble MICA. Cancer Immunol Immunother 2006;55:1584-1589. (Pubitemid 44327846)
22. Holdenrieder S, Stieber P, Peterfi A, Nagel D, Steinle A, and Salih HR: Soluble MICA in malignant diseases. Int J Cancer 2006;118:684-687. (Pubitemid 43076018)
23. Marten A, von Lilienfeld-Toal M, Buchler MW, and Schmidt J: Soluble MIC is elevated in the serum of patients with pancreatic carcinoma diminishing gammadelta T cell cytotoxicity. Int J Cancer 2006;119:2359-2365. (Pubitemid 44546956)
24. Cao W, Xi X, Wang Z, Dong L, Hao Z, Cui L, Ma C, and He W: Four novel ULBP splice variants are ligands for human NKG2D. Int Immunol 2008;20:981-991.
25. Pende D, Rivera P, Marcenaro S, Chang CC, Biassoni R, Conte R, Kubin M, Cosman D, Ferrone S, Moretta L, and Moretta A: Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity. Cancer Res 2002;62:6178-6186. (Pubitemid 35244469)
26. Liu B, Li G, Sui X, Yin J, Wang H, and Ren X: Expression and functional analysis of porcine aminopeptidase N produced in prokaryotic expression system. J Biotechnol 2009;141: 91-96.
27. Zhang C, Zhang J, Wei H, and Tian Z: Imbalance of NKG2D and its inhibitory counterparts: How does tumor escape from innate immunity? Int Immunopharmacol 2005;5:1099-1111. (Pubitemid 40725706)